Moberg Pharma AB (publ)
STO:MOB

Watchlist Manager
Moberg Pharma AB (publ) Logo
Moberg Pharma AB (publ)
STO:MOB
Watchlist
Price: 9.3 SEK 1.86% Market Closed
Market Cap: 453m SEK

Wall Street
Price Targets

MOB Price Targets Summary
Moberg Pharma AB (publ)

Wall Street analysts forecast MOB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MOB is 13.26 SEK with a low forecast of 13.13 SEK and a high forecast of 13.65 SEK.

Lowest
Price Target
13.13 SEK
41% Upside
Average
Price Target
13.26 SEK
43% Upside
Highest
Price Target
13.65 SEK
47% Upside
Moberg Pharma AB (publ) Competitors:
Price Targets
COHANCE
Cohance Lifesciences Ltd
54% Upside
RPRX
Royalty Pharma PLC
19% Upside
600521
Zhejiang Huahai Pharmaceutical Co Ltd
22% Upside
CRON
Cronos Group Inc
26% Upside
NATCOPHARM
Natco Pharma Ltd
2% Upside
DRREDDY
Dr Reddy's Laboratories Ltd
5% Upside
GRANULES
Granules India Ltd
7% Upside
4552
JCR Pharmaceuticals Co Ltd
8% Downside

Revenue
Forecast

Revenue Estimate
Moberg Pharma AB (publ)

The compound annual growth rate of Moberg Pharma AB (publ)'s revenue for the next 3 years is 79%.

N/A
Past Growth
79%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Moberg Pharma AB (publ)

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Moberg Pharma AB (publ)

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MOB's stock price target?
Price Target
13.26 SEK

According to Wall Street analysts, the average 1-year price target for MOB is 13.26 SEK with a low forecast of 13.13 SEK and a high forecast of 13.65 SEK.

What is Moberg Pharma AB (publ)'s Revenue forecast?
Projected CAGR
79%

The compound annual growth rate of Moberg Pharma AB (publ)'s revenue for the next 3 years is 79%.

Back to Top